Patents by Inventor Mitchell A. deLong

Mitchell A. deLong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY
    Publication number: 20180333405
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Application
    Filed: February 21, 2018
    Publication date: November 22, 2018
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
    Publication number: 20180327381
    Abstract: Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.
    Type: Application
    Filed: March 30, 2018
    Publication date: November 15, 2018
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
  • Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
    Patent number: 10112920
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: October 30, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20180244666
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: March 30, 2018
    Publication date: August 30, 2018
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
  • DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20180215749
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: March 16, 2018
    Publication date: August 2, 2018
    Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
  • 6-AMINOISOQUINOLINE COMPOUNDS
    Publication number: 20180186746
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 5, 2018
    Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
  • BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS
    Publication number: 20180170898
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 21, 2018
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Combination therapy
    Patent number: 9993470
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 12, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Beta-amino-isoquinolinyl amide compounds
    Patent number: 9963432
    Abstract: Disclosed are alpha-aryl-beta-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing isoquinoline amide compounds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 8, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Jill M. Sturdivant, Mitchell A. deLong, Susan M. Royalty
  • Dual mechanism inhibitors for the treatment of disease
    Patent number: 9951059
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 24, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Combination therapy
    Patent number: 9931336
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 3, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH
    Publication number: 20180064622
    Abstract: A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.
    Type: Application
    Filed: April 12, 2017
    Publication date: March 8, 2018
    Inventors: Mitchell A. deLong, Elise A. Olsen
  • OPHTHALMIC COMPOSITIONS
    Publication number: 20180055833
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Application
    Filed: August 30, 2017
    Publication date: March 1, 2018
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • BETA-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
    Publication number: 20180050990
    Abstract: Disclosed are alpha-aryl-beta-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing isoquinoline amide compounds.
    Type: Application
    Filed: March 31, 2017
    Publication date: February 22, 2018
    Inventors: Jill M. Sturdivant, Mitchell A. deLong, Susan M. Royalty
  • 6-aminoisoquinoline compounds
    Patent number: 9890123
    Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 13, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
  • Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
    Patent number: 9884840
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: February 6, 2018
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
    Patent number: 9877908
    Abstract: A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: January 30, 2018
    Assignee: Duke University
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
  • Combination therapy
    Patent number: 9849122
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 26, 2017
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Methods for the preparation of 6-aminoisoquinoline
    Patent number: 9840468
    Abstract: Described are methods for the preparation of 6-aminoisoquinoline, a useful intermediate compound in the synthesis of kinase inhibitors.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: December 12, 2017
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Gilles Chambournier, Mitchell A. deLong
  • COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS
    Publication number: 20170348214
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Application
    Filed: January 18, 2017
    Publication date: December 7, 2017
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist